Aclaris Therapeutics Announced Phase 1b Proof-of-Concept Primary Analysis Results For ATI-052 In Atopic Dermatitis, Asthma, Demonstrating Rapid, Durable Skin, Itch Improvement, Improved Lung Function, Airway Inflammation
Share
Why It Matters
Aclaris tested a new medicine on people with itchy skin and asthma. Early results looked good, which means the company might be making something helpful.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.